Drug – bio-affecting and body treating compositions – Designated organic nonactive ingredient containing other... – Carboxylic acid or salt thereof
Reexamination Certificate
2011-08-23
2011-08-23
Pryor, Alton (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic nonactive ingredient containing other...
Carboxylic acid or salt thereof
C514S785000
Reexamination Certificate
active
08003706
ABSTRACT:
The blood collection, processing and transfer by separation of discrete components containing additional citrate (at least about trisodium citrate 9% w/v) in one or other of collection or processing bag provides for enhanced yield and purity of cryoprecipitate. Inhibiting the activation or denaturation of blood components including blood cells and plasma proteins and with the removal of the activated and denatured components thereby improving safety and efficacy of end products. The inventive process is particularly suited to an improved extraction process to yield concentrated clotting factors from single donors or limited pools without use of chromatography. Following extraction the remaining cryoprecipitate can advantageously be formed into a fibrin fabric used in surgeries and in the treatment of wounds.
REFERENCES:
patent: 3560475 (1971-02-01), Fekete et al.
patent: 3631018 (1971-12-01), Shanbrom
patent: 3682881 (1972-08-01), Fekete et al.
patent: 3803115 (1974-04-01), Fekete et al.
patent: 4025654 (1977-05-01), Farhadieh
patent: 4069219 (1978-01-01), Weier
patent: 4086218 (1978-04-01), Shanbrom
patent: 4305871 (1981-12-01), Shanbrom
patent: 4327086 (1982-04-01), Fukushima et al.
patent: 4925665 (1990-05-01), Murphy
patent: 4977246 (1990-12-01), Lee et al.
patent: 5196428 (1993-03-01), Meanwell
patent: 5459030 (1995-10-01), Lin et al.
patent: 5656591 (1997-08-01), Tomita et al.
patent: 5660731 (1997-08-01), Piechocki et al.
patent: 5770704 (1998-06-01), Godowski
patent: 5875799 (1999-03-01), Petrus
patent: 5981254 (1999-11-01), Bui-Khac
patent: 5985260 (1999-11-01), Shanbrom
patent: 6037116 (2000-03-01), Wiggins et al.
patent: 6403381 (2002-06-01), Mann et al.
patent: 7411006 (2008-08-01), Shanbrom
patent: 627020 (1962-02-01), None
patent: 3316464 (1984-11-01), None
patent: 188008 (1986-07-01), None
patent: 0272551 (1998-06-01), None
patent: 2033611 (1995-04-01), None
patent: WO8900006 (1989-01-01), None
patent: WO 93/04678 (1993-03-01), None
patent: WO 93/21933 (1993-11-01), None
patent: WO 96/18292 (1996-06-01), None
patent: WO 9822151 (1998-05-01), None
J.L. Vernon et al., “Comined Cohn/chromatography purification process for the manufacturing of high pruity human albumin from plasma”, 1993, pp. 183-188.
K. Pederson, “Inhibition of bacterial haemolysis on blood agar medium by oxalate or citrate used as anticoagulants”, 1973, pp. 384.
D. Thompson et al., “Fibrin glue: a review of its preparation, efficacy, and adverse effects as a tropic hemostat”, 1988, pp. 946-952.
S. Arrighi et al., “Process for the isolation of highly purified factors IX, X and II from prothrombin complex or human plasma”, 1996, pp. 183-299 (Abstract).
Oldurova, Problemy Gematol., i Perelivan. Krovi., 1961, 6 No. 11, 52-5. Abstract Only.
Brown et al, “The stability of suspensions from solid dosage forms”, 1976, J. Clin. Pharm., vol. 1 No. 1, pp. 29-37.
International Search Report for PCT/US02/03996, 2002.
Kirchanski Stefan J.
Pryor Alton
Shanbrom Technologies LLC
Venable LLP
LandOfFree
Enhanced production of blood clotting factors and fibrin fabric does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Enhanced production of blood clotting factors and fibrin fabric, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Enhanced production of blood clotting factors and fibrin fabric will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-2694699